Organic compounds -- part of the class 532-570 series – Organic compounds – Heterocyclic carbon compounds containing a hetero ring...
Patent
1991-11-05
1993-03-09
Mars, Howard T.
Organic compounds -- part of the class 532-570 series
Organic compounds
Heterocyclic carbon compounds containing a hetero ring...
560255, 562404, 568326, 552295, 552298, 552299, C07C 49215, C07C 5032, C07D30777
Patent
active
051928175
DESCRIPTION:
BRIEF SUMMARY
FIELD OF THE INVENTION
The present invention relates to novel phenanthrene derivatives, salts thereof, production processes therefor, and interleukin-1 (IL-1) inhibitors containing the novel phenanthrene derivatives as active ingredients.
PRIOR ART
The phenanthrene derivatives of the present invention are novel compounds not disclosed in any literature.
In the Second International Lymphokine Workshop, it was decided that a standard name of interleukin-1 (IL-1) be given to all of the physiologically active substances which had been reported under various names such as Lymphocyte Activating Factor (LAF), Mitogenic Protein, Helper peak-1, T-cell replacing factor III (TRF-III), T-cell replacing factor macrophage (TRFM), B-cell activating factor, B-cell differentiation factor and the like [Cellular Immunol., 48. 433-436 (1979)]. The decision is based on the ground that each of the above physiologically active substances cannot be distinguished from others as a different substance and that each conventional name merely indicates a physiological activity viewed from a different angle.
The IL-1 is known as an important biologically active substance which induces and transfers systemic biological reactions such as infection and inflammation, and has by itself a strong antitumor activity [Hirai, Y. et al.: "Gann Monograph on Cancer Research", Japan Scientific Societies Press, Tokyo (1988)]. Also, the IL-1 has been confirmed to induce biological reactions which are seen in the human body during inflammation, such as pyrexia, increase in white blood cell count, activation of lymphocyte, induction of hepatic acute phase protein synthesis, and the like [Dinarello, C. A.: Interleukin-1; Rev. Infect. Dis., 6, 51-95 (1984), Kluger, M. J., Oppenheim, J. J. & Powanda, M. C.; The Physiologic, Metabolic and Immunologic Actions of interleukin-1; Alan R. Liss, Inc., New York (1985)].
The IL-1 has various biological activities and is thought to be a biologically active substance necessary for the maintenance of homeostatis of the human body. However, if the controlling function for IL-1 production becomes abnormal to give rise to accentuation of IL-1 production and resultant excessive production of IL-1, it would cause various diseases. In rheumatoid arthritis, for example, it is reported that there are strong relationships between production of IL-1 by synovium and degree of inflammation of arthricular synovial membrane, and between production of IL-1 by synovium and degree of joint changes and between production of IL-1 by synovium and degree of HLA-DR antigen expression in synovial membrane [Miyasaka, N., Sato, K., Goto, M., Sasano, M., Natsuyama, M., Inoue, K. and Nishioka, K.: Augmented interleukin-1 production and HLA-DR expression in the synovium of rheumatoid arthritis patient; Arthritis Rheum., 31, (4), 480-486, (1988)].
It is therefore considered that the inhibition of excessive IL-1 release from cells could block various physiological activities in which the IL-1 participates.
Currently, glucocorticoid hormone is in use as a treating agent for chronic inflammatory diseases, and part of the activities is known to lie in the inhibition of IL-1 production [Lew, W., Oppenheim, J. J. & Matsushima, K.; Analysis of the suppression of IL-1.alpha. and IL-1.beta. production in human peripheral blood mononuclear adherent cells by a glucocorticoid hormone; J. Immunol., 140, (6), 1895-1902 (1988)]. However, the glucocorticoid is known to cause, as a disadvantage, various severe side-effects owing to multiple physiological activities.
Hence in the pharmaceutical industry, particularly in the field for treating chronic inflammatory diseases, there is now desired the development of a novel substance which has no side-effects as seen in glucocorticoid, which has excellent safety in other toxicities and side-effects, and which has high selectivity.
Compounds having structural formulas similar to those of the phenanthrene derivatives of the present application are disclosed in the following literatures (1)-(19): 330-332, (Eng.) 172-5
REFERENCES:
Chemical Abstracts, 101 (7) Aug., 13, 1984, p. 645, 55371f: Bull. Chem. Soc. Japan, 1984, 57 (3) pp. 747-751.
Chemical Abstracts, 108 (13) Mar. 28, 1988, p. 664, 112783h.
Chemical Abstracts, 107 (13) Sep. 28, 1987, p. 369, 112684k: Yaoxue Xuebao, 1987, 22 (5) pp. 377-379.
Asakuni Takahiro
Goto Kiyoto
Kuwahara Toshiko
Manabe Sachiko
Ono Yukihisa
Kestler Kimberly J.
Mars Howard T.
Otsuka Pharmaceutical Co. Ltd.
Otsuka Pharmaceutical Factory Inc.
LandOfFree
Phenanthrene derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Phenanthrene derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Phenanthrene derivatives will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-212084